Clearside Biomedical, Inc. (CLSDQ) — SEC Filings
Clearside Biomedical, Inc. (CLSDQ) — 32 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 21 8-K, 6 10-Q, 3 DEF 14A.
View Clearside Biomedical, Inc. on SEC EDGAR
Overview
Clearside Biomedical, Inc. (CLSDQ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Clearside Biomedical, Inc. filed an 8-K on December 8, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The company, incorporated in Delaware, is in the pharmaceutical preparations industry.
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 8 bearish, 24 neutral. The dominant filing sentiment for Clearside Biomedical, Inc. is neutral.
Filing Type Overview
Clearside Biomedical, Inc. (CLSDQ) has filed 21 8-K, 6 10-Q, 3 DEF 14A, 2 10-K with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of CLSDQ's 29 recent filings, 8 were flagged as high-risk, 10 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3.02M |
| Net Income | -$18.69M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $6.8M |
| Operating Margin | N/A |
| Total Assets | $11.64M |
| Total Debt | $65.59M |
Key Executives
- Charles Deignan
Industry Context
Clearside Biomedical operates in the highly competitive biopharmaceutical sector, focusing on treatments for retinal diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Clearside face intense competition from both established pharmaceutical giants and emerging biotech firms, requiring continuous innovation and strategic partnerships to succeed.
Top Tags
delisting (5) · financials (4) · corporate-governance (4) · 10-Q (4) · listing-standards (3) · Biotechnology (3) · corporate-action (3) · filing (3) · material-agreement (3) · financial-reporting (3)
Executive Compensation
From the most recent DEF 14A filing (Aug 4, 2025):
- Charles Deignan — Chief Financial Officer
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $6.8M | As of September 30, 2025, down from $20.02 million at December 31, 2024. |
| Net loss | $5.97M | For the three months ended September 30, 2025, an improvement from $7.69 million in 2024. |
| License and other revenue | $201K | For the three months ended September 30, 2025, a decrease from $1.04 million in 2024. |
| Severance and employee termination costs | $2.3M | Incurred during the three months ended September 30, 2025, due to Reduction in Force. |
| Reverse stock split ratio | 1:15 | Effected on September 12, 2025. |
| Shares of common stock outstanding | 5,233,981 | As of November 12, 2025. |
| Net proceeds from at-the-market sales | $1.4M | From selling 109,957 shares during the nine months ended September 30, 2025. |
| Total stockholders' deficit | $53.95M | As of September 30, 2025, an increase from $38.86 million at December 31, 2024. |
| Commission File Number | 001-37783 | Identifier for Clearside Biomedical's SEC filings |
| IRS Employer Identification No. | 45-2437375 | Tax identification number for Clearside Biomedical |
| SEC File Number | 001-37783 | Identifies the company's filing history with the SEC. |
| New Fiscal Year End | 1231 | The company has updated its fiscal year end to December 31. |
| Net Loss (Q2 2025) | $10.1M | Narrows from $10.7M in Q2 2024, but still significant. |
| Net Loss (YTD 2025) | $20.9M | Increased from $19.9M in YTD 2024, indicating growing cumulative losses. |
| Revenue (Q2 2025) | $1.5M | Primarily from XIPERE, a decrease from $2.0M in Q2 2024. |
Forward-Looking Statements
- {"claim":"Clearside Biomedical will release more details about the Material Definitive Agreement.","entity":"Clearside Biomedical, Inc.","targetDate":"Q1 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Clearside Biomedical, Inc. (CLSDQ)?
Clearside Biomedical, Inc. has 32 recent SEC filings from Feb 2024 to Dec 2025, including 21 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLSDQ filings?
Across 32 filings, the sentiment breakdown is: 8 bearish, 24 neutral. The dominant sentiment is neutral.
Where can I find Clearside Biomedical, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Clearside Biomedical, Inc. (CLSDQ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Clearside Biomedical, Inc.?
Key financial highlights from Clearside Biomedical, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CLSDQ?
The investment thesis for CLSDQ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Clearside Biomedical, Inc.?
Key executives identified across Clearside Biomedical, Inc.'s filings include Charles Deignan.
What are the main risk factors for Clearside Biomedical, Inc. stock?
Of CLSDQ's 29 assessed filings, 8 were flagged high-risk, 10 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Clearside Biomedical, Inc.?
Recent forward-looking statements from Clearside Biomedical, Inc. include guidance on {"claim":"Clearside Biomedical will release more details about the Material Definitive Agreement.","entity":"Clearside B.